EE272 Treating Patients With Non-Valvular Atrial Fibrillation With Apixaban Provides Substantial Consumer Value and Surplus Compared With Warfarin and Rivaroxaban
| Autor: | Johannesen, K, Atreja, N, Subash, R, Bektur, C, Hagan, M, Hines, D, Dunnett, I, Stawowczyk, E |
|---|---|
| Zdroj: | In Value in Health June 2024 27(6) Supplement:S107-S107 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect